Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and high plasma homocysteine in chronic hepatitis C (CHC) infected patients from the Northeast of Brazil

Nutrition Journal

Flair J Carrilho¹  Leila MMB Pereira²  Filipe Silva³  Maria TC Muniz³  Cláudia PMS Oliveira¹  Erika RF Siqueira² 

[1] Department of Gastroenterology LIM-07, University of Sao Paulo School of Medicine, Avenue Dr Arnaldo, 455, Sao Paulo, 01246903, Brazil;Liver Institute of Pernambuco, Arnóbio Marques Street, 282, Pernambuco,50.100-130, Pernambuco, Brazil;Departments of Biochemistry, University of Pernambuco School of Medicine, Avenue Agamenon Magalhães, Pernambuco, 50.100-010, Brazil

关键词: Homocysteine;    Steatosis;    Genotype 1;    MTHFR;    Hepatitis C;   

Others  :  828913
DOI  :  10.1186/1475-2891-10-86

 received in 2011-05-06, accepted in 2011-08-19,  发布年份 2011

【 摘 要 】

Background/Aim

Hyperhomocysteinemia due to Methylenetetrahydrofolate Reductase (MTHFR) gene, in particular the C677T (Ala222Val) polymorphism were recently associated to steatosis and fibrosis. We analyzed the frequency of MTHFR gene in a cross-sectional study of patients affected by Chronic Hepatitis C (CHC) from Northeast of Brazil.

Method

One hundred seven-four untreated patients with CHC were genotyped for the C677T MTHFR. Genomic DNA was extracted from peripheral blood cells and the C677T MTHFR polymorphism was identified by PCR-RFLP. The homocysteine (Hcy) levels were determined by chemiluminescence method. All patients were negative for markers of Wilson's disease, hemochromatosis and autoimmune diseases and have current and past daily alcohol intake less than 100 g/week.

Results

Among subjects infected with CHC genotype non-1 the frequency of MTHFR genotypes TT was 9.8% versus 4.4% genotype 1 (p = 0.01). Nevertheless, association was found between the MTHFR genotype TT × CT/CC polymorphism and the degree of steatosis and fibrosis in both hepatitis C genotype (p < 0.05). A significant difference was found on plasma Hcy levels in patients with steatosis regardless of HCV genotype (p = 0.03).

Conclusion

Our results indicate that plasma Hcy levels is highly prevalent in subjects with chronic hepatits C with steatosis regardless of HCV genotype and vitamin deficiency. The presence of genotype TT of MTHFR C677T polymorphism was more common in CHC genotype non-1 infected patient regardless of histopathological classification and genotype TT+CT frequencies were significant in the presence of fibrosis grade 1+2 and of steatosis in CHC infected patients from the northeast of Brazil regardless of HCV genotype. The genetic susceptibility of MTHFR C677T polymorphism should be confirmed in a large population.

【 授权许可】

   
2011 Siqueira et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Refsun H, Ueland P, Nygard O, Vollset SE: Homocysteine and cardiovascular disease. Annu Rev Med 1998, (49):31-62.
• [2]Bostom AG, Lathrop L: Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerosis outcomes. Kidney Int 1997, 52:10-20.
• [3]Eskes TKAB: Open or closed? A word of differences: A history of homocysteine research. Nutr Rev 1998, 56:236-244.
• [4]Lehmann M, Gottfries CG, Regland B: Identification of cognitive impairment in the elderly: Homocysteine is an early marker. Dementia 1999, 10:12-20.
• [5]Ji C, Kaplowitz N: Betaine decreases hyperyhomocysteinemia, endoplasmic reticulum stress, and liver injury in alcohol-fed mice. Gastroenterology 2003, 124:1488-1499.
• [6]Goyette P, Sumner JS, Milos R, Duncan AM, Rosenblatt DS, Matthews RG, Rozen R: Human methylenetetrahydro folate reductase: isolation of cDNA, mapping and mutation identification. Nat Gen 1994, 7:195-200.
• [7]Van der Put NMJ, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, van den Heuvel LP, Blom HJ: A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J HumGenet 1998, 62:1044-1051.
• [8]Andreassi MG, Botto N, Battaglia D, Antonioli E, Masetti S, Manfredi S, Colombo MG, Biagini A, Clerico A: Methylenetetrahydro folate reductase gene C677T polymorphism, homocysteine, vitamin B12, and DNA damage in coronary artery disease. HumGenet 2003, 112:171-177.
• [9]Rozen R: Polymorphisms of folate and cobalamin metabolism. Edited by Carmel R, Jacobsen DW. Homocysteine in Health and Disease. UK: Cambridge University Press; 2001:259-270.
• [10]Adinolfi LE, Ingrosso D, Cesaro G, Cimmino A, D'Antò M, Capasso R, Zappia V, Ruggiero G: Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. Hepatology 2005, 41:995-1003.
• [11]Finelli L, Alter MJ: Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5:558-56.7.
• [12]Negro F, Sanyal AJ: Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver Int 2009, (29):Suppl 2, 26-37.
• [13]Fiore G, Fera G, Napoli N, Vella F, Schiraldi O: Liver steatosis and chronic hepatitis C: a spurious association? Eur J Gastroenterol Hepatol 1996, 8:125e129.
• [14]Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallee M, Heaton S, Conrad A, Pockros PJ, McHutchison JG: The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004, 40:484-490.
• [15]Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male PJ, Giostra E, Carlotto A, Bozzola L, Smedile A, Negro F: Steatosis affects chronic hepatitisC progression in a genotype specific way. Gut 2004, 53:406-12.
• [16]Castera L, Hezode C, Roudot-Thoraval F, Lonjon I, Zafrani ES, Pawlotsky JM, Dhumeaux D: Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut 2004, 53:420-4.
• [17]Hezode C, Roudot-Thoraval F, Zafrani ES, Dhumeaux D, Pawlotsky JM: Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. J Viral Hepat 2004, 11:455-8.
• [18]Gruady SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA: Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004, 109:551-6.
• [19]Matthews DR, Hosker JP, Rudesnki AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from plasma fasting blood sugar and insulin concentration in man. Diabetologia 1985, 28:412-419.
• [20]Mindicino HJ, Carlsen J, Tewari P, Aagaard O, Zhang B, Conarpe C: An evaluation of an automated homocysteine method on the Bayer ADVIA Centaur automated chemiluminescent system. Clin Lab 2002, 48:493-496.
• [21]Friedewald WT, Levi RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein in plasma, without the use of preparative ultracentrifuge. Clin Chem 1992, 21:1983-1985.
• [22]Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, et al.: A candidate genetic risk factor for vascular disease: A common mutation at the methylenetetrahydrofolate reductase locus. Nature Gen 1995, 10(1):111-113.
• [23]Almawi WY, Ameen G, Tamim H, Finan RR, Irani-Hakime N: Factor V G1691A, prothrombin G20210A, and methylenetetrahydrofolate reductase [MTHFR] C677T gene polymorphism in angiographically documented coronary artery disease. J Thromb Thrombolysis 2004, 17:199-205.
• [24]Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y, Maemura K, Shindo T, Minamino T, Ohno M, Yamaoki K, Ogasawara K, Aizawa T, Suzuki S, Yazaki Y: Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation 1997, 95:2032-2036.
• [25]Jee SH, Beaty TH, Suh I, Yoon Y, Appel LJ: The methylenetetrahydrofolate reductase gene is associated with increased cardiovascular risk in Japan, but not in other populations. Atherosclerosis 2000, 153:161-168.
• [26]Toniutto P, Fabris C, Falleti E, Cussigh A, Fontanini E, Bitetto D, Fornasiere E, Minisini R, De Feo T, Marangoni F, Pirisi M: Methylenetetrahydrofolate reductase C677T polymorphismand liver fibrosis progression in patients with recurrent hepatitis C. Liver International 2007, 273-263.
• [27]Borgia G, Gentile I, Fortunato G, Borrelli F, Borelli S, de Caterina M, Di Taranto MD, Simone M, Borgia F, Viola C, Reynaud L, Cerini R, Sacchetti L: Homocysteine levels and sustained virological response to pegylatedinterferon α2b plus ribavirin therapy for chronic hepatitis C:a prospective study. Liver International 2008, 248-252.
• [28]da Silva VC, Ramos FJ, Freitas EM, de Brito-Marques PR, Cavalcanti MN, D'Almeida V, Cabral-Filho JE, Muniz MT: Alheimer's Disease in Brazilian Elderly has a Relation With Homocysteine but not with MTHFR polymorphisms. Arq Neuropsiquiatr 2006, 64(4):941-945.
• [29]Couto FD, Adorno EV, Menezes JF, MouraNeto JP, dos Reis MG: C677T polymorphism of the MTHFR gene and variant haemoglobin: a study in newborns from Salvador,Bahia, Brazil. Cad Saude Publica 2004, 20(2):529-533.
• [30]Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP: Steatosis and hepatitis C: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004, 126:586-597.
• [31]Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, Palma-Reis RJ, Boers GH, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Lúis AC, Parrot-Rouland FM, Tan KS, Higgins I, Garcon D, Andria G, et al.: Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997, 277:1775-81.
• [32]Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I: Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991, 324:1149-55.
• [33]Den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM: Hyperhomocysteinemia and venous thrombosis: a metaanalysis. Thromb Haemost 1998, 80:874-7.
• [34]Cattaneo M: Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999, 81:165-76.
• [35]Melvin Hayden R, Suresh Tyagi C: Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: The pleiotropic effects of folate supplementation. Nutrition Journal 2004, 3:4. BioMed Central Full Text
• [36]Garcia-Tevijano ER, Berasain C, Rodriguez JA, Corrales FJ, Arias R, Martín-Duce A, Caballería J, Mato JM, Avila MA: Hyperhomocysteinemia in liver cirrhosis: mechanisms and role in vascular and hepatic fibrosis. Hypertension 2001, 38:1217-21.
• [37]Torres L, Garcia-Trevijano E R, Rodriguez JA, Carretero MV, Bustos M, Fernández E, Eguinoa E, Mato JM, Avila MA: Induction of TIMP-1 expression in rat hepatic stellate cells and hepatocytes: a new role for homocysteine in liver fibrosis. Biochim Biophys Acta 1999, 1455:12-22.
• [38]Kang SS, Zhou J, Wong PW, Kowalisyn J, Strokosch G: Intermediate homocysteinemia:a thermolabile variant of methylenetetrahydrofolate reductase. AmJ Hum Genet 1988, 43:414-421.
• [39]Finkelstein JD, Martin JJ, Harris BJ: Methionine metabolism in mammals. The methionine-sparing effect of cystine. J Biol Chem 1988, 263:11750-11754.
• [40]Upchurch GR, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF, Loscalzo J: Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. JBiol Chem 1997, 272:17012-17017.
• [41]Outinen PA, Sood SK, Liaw PC, Sarge KD, Maeda N, Hirsh J, Ribau J, Podor TJ, Weitz JI, Austin RC: Characterization of the stress-inducing effects of homocysteine. Biochem J 1998, 332:213-221.
• [42]Dayal S, Brown KL, Weydert CJ, Oberley LW, Arning E, Bottiglieri T, Faraci FM, Lentz SR: Deficiency of glutathione peroxidase-1 sensitizes hyperhomocysteinemic mice to endothelial dysfunction. Arterioscler Thromb Vasc Biol 2002, 22:1996-2002.
• [43]Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D: Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit andman. J Clin Invest 1989, 84:1086-1095.
• [44]Werstuck GH, Lentz SR, Dayal S, Hossain GS, Sood SK, Shi YY, Zhou J, Maeda N, Krisans SK, Malinow MR, Austin RC: Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest 2001, 107:1263-73.
• [45]Andre P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, Pol S, Bréchot C, Paranhos-Baccalà G, Lotteau V: Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002, 76:6919-6928.
• [46]Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX: Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999, 96:12766-12771.
• [47]Molina S, Castet V, Fournier-Wirth C, Pichard-Garcia L, Avner R, Harats D, Roitelman J, Barbaras R, Graber P, Ghersa P, Smolarsky M, Funaro A, Malavasi F, Larrey D, Coste J, Fabre JM, Sa-Cunha A, Maurel P: The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol 2007, 46:411-419.